Paloma Partners Management CO Gilead Sciences, Inc. Call Options Transaction History

Paloma Partners Management CO

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $8.2 Million - $9.46 Million	-129,795 Reduced 91.93%	11,400 $782,000
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $9.16 Million - $11.2 Million	127,995 Added 969.66%	141,195 $10.3 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $4.32 Million - $4.89 Million	-58,900 Reduced 81.69%	13,200 $1.07 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $5.33 Million - $5.82 Million	72,100 New	72,100 $5.4 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $17.8 Million - $20.1 Million	-308,700 Reduced 89.35%	36,800 $2.27 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $19.6 Million - $24.6 Million	338,500 Added 4835.71%	345,500 $20.5 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $4.29 Million - $4.74 Million	-68,700 Reduced 90.75%	7,000 $444,000
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $4.73 Million - $5.3 Million	75,700 New	75,700 $4.92 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $2.59 Million - $2.87 Million	-36,400 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $1.63 Million - $1.9 Million	-25,100 Reduced 40.81%	36,400 $2.58 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $3.02 Million - $3.69 Million	-41,500 Reduced 40.29%	61,500 $4.64 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $12.1 Million - $14.3 Million	-170,700 Reduced 62.37%	103,000 $7.38 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $19.7 Million - $23.4 Million	273,700	273,700 $22.2 Million

1,931

991M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.